Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (286)	10/25/2002 1:49:28 AM
From: Dave	Respond to of 370

Strange, but that press release doesn't suggest any possible basis for an appeal of the delisting. But the question is moot. A thousand VION shares sell for $250, and you have to pay $60 to a discount broker like Charles Schwab for each thousand shares you buy and sell. That's a 24% hit for placing a bet on a company that's going to be delisted and whose cash reserves will be dry before it has a chance of seeing any more capital. And you'll pay more at a full-service broker like Merrill "trust us would we lie?" Lynch. Dave